Virginia is currently home to 1836 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Richmond, Charlottesville, Norfolk and Fairfax. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
NCT06904261
Recruiting
An open-label study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of migalastat treatment in pediatric subjects 2 to \< 12 years of age with Fabry disease and with amenable GLA variants.
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
06/05/2025
Locations: Lysosomal and Rare Disorders Research and Treatment Center, Inc., Fairfax, Virginia
Conditions: Fabry Disease
Register for Updates
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
NCT06779773
Recruiting
This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a person's central vision to worsen. Geographic atrophy is an advanced form of AMD where cells in the retina waste away and die. Over time this can lead to permanent loss of vision. Avacincaptad pegol can help slow down the worsening or progression of geographic atrophy. Ava... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/05/2025
Locations: Piedmont Eye Center, Inc., Lynchburg, Virginia
Conditions: Geographic Atrophy, Macular Degeneration
Register for Updates
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
NCT06743126
Recruiting
This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommended phase 2 dose versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Melanoma, Cutaneous Malignant
Register for Updates
A Study to Assess the Efficacy and Safety of Induction Therapy With RO7790121 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06588855
Recruiting
This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with RO7790121 compared with placebo in participants with moderately to severely active ulcerative colitis (UC).
Gender:
ALL
Ages:
Between 16 years and 80 years
Trial Updated:
06/05/2025
Locations: Emeritas Research Group, Lansdowne Town Center, Virginia
Conditions: Moderately to Severely Active Ulcerative Colitis
Register for Updates
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
NCT06556563
Recruiting
This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the study is to evaluate the Overall Survival (OS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Inova Schar Cancer Institute, Fairfax, Virginia
Conditions: Glioblastoma
Register for Updates
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
NCT06470451
Recruiting
To evaluate the use of HyBryte, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Inova Schar Cancer Institute, Fairfax, Virginia
Conditions: CTCL/ Mycosis Fungoides, CTCL, Mycosis Fungoides, Cutaneous T Cell Lymphoma
Register for Updates
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
NCT06425302
Recruiting
The purpose of this study is to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma (FL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Local Institution - 0200, Norfolk, Virginia
Conditions: Lymphoma, Follicular
Register for Updates
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
NCT06373731
Recruiting
The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular degeneration (AMD). The main questions it aims to answer are: what is the rate of change in the macular area of photoreceptor loss in subjects who receive a daily dose of elamipretide compared with those who receive a look-alike substance that contains no active drug, and what is the safety and tolerability of elamipretide daily subcutaneous injections... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
06/05/2025
Locations: Emerson Clinical Research Institute, Falls Church, Virginia
Conditions: Age Related Macular Degeneration (ARMD)
Register for Updates
A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure
NCT06299826
Recruiting
The main purpose of this study is to evaluate the effect of AZD5462 on cardiac function in participants with chronic heart failure (HF).
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/05/2025
Locations: Research Site, Manassas, Virginia
Conditions: Chronic Heart Failure
Register for Updates
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873
Recruiting
The purpose of this study is to measure the efficacy and safety of baxdrostat/dapagliflozin in participants ≥ 18 years of age with CKD and HTN. This study consists of a screening, a 4-week dapagliflozin run-in period for participants naïve to SGLT2i at baseline; a 24-month double-blind period in which participants will receive either baxdrostat/dapagliflozin or dapagliflozin; and a 6-week open-label period in which all participants will discontinue baxdrostat/placebo and receive dapagliflozin a... Read More
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
06/05/2025
Locations: Research Site, Arlington, Virginia
Conditions: Chronic Kidney Disease and Hypertension
Register for Updates
A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
NCT06130553
Recruiting
This is a first time in human (FTiH) Phase I/IIa, open-label, multi-centre study of AZD3470 in participants with advanced or metastatic solid tumors with MTAP deficiency. The study consists of several study modules, evaluating the safety, tolerability, pharmacokinetic (PK), pharmacodynamics, and preliminary efficacy of AZD3470 as monotherapy or in combination with other anti-cancer agents.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Research Site, Fairfax, Virginia
Conditions: Advanced Solid Tumors That Are MTAP Deficient
Register for Updates
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT06073821
Recruiting
The main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Virginia Cancer Institute, Richmond, Virginia
Conditions: CLL
Register for Updates